KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) EBT Margin (2017 - 2025)

Amneal Pharmaceuticals has reported EBT Margin over the past 9 years, most recently at 6.78% for Q4 2025.

  • Quarterly results put EBT Margin at 6.78% for Q4 2025, up 888.0% from a year ago — trailing twelve months through Dec 2025 was 4.61% (up 658.0% YoY), and the annual figure for FY2025 was 4.61%, up 658.0%.
  • EBT Margin for Q4 2025 was 6.78% at Amneal Pharmaceuticals, up from 0.67% in the prior quarter.
  • Over the last five years, EBT Margin for AMRX hit a ceiling of 7.14% in Q2 2025 and a floor of 41.61% in Q2 2022.
  • Median EBT Margin over the past 5 years was 0.01% (2022), compared with a mean of 1.74%.
  • Biggest five-year swings in EBT Margin: crashed -4812bps in 2022 and later surged 4656bps in 2023.
  • Amneal Pharmaceuticals' EBT Margin stood at 3.04% in 2021, then surged by 59bps to 1.26% in 2022, then plummeted by -978bps to 13.53% in 2023, then surged by 84bps to 2.1% in 2024, then soared by 423bps to 6.78% in 2025.
  • The last three reported values for EBT Margin were 6.78% (Q4 2025), 0.67% (Q3 2025), and 7.14% (Q2 2025) per Business Quant data.